State coverage
Medicaid, for obesity: Does not cover. The conditions and the appeal deadline are in the summary below.
Illinois says no in three separate documents, which is more consistency than most states manage. The administrative rule excludes anorectic drugs from pharmacy coverage. The pharmacy handbook, in plainer words, lists weight loss drugs among the things the program does not pay for. And the state's own prior-authorization criteria for this drug class put Wegovy, Zepbound and Saxenda under a heading that reads, simply, not covered agents.
Those criteria are also where you can see the reasoning stated as a rule rather than implied. One of the listed reasons a request gets refused is that the medication is being used for obesity alone or together with a condition caused by obesity. Every approval pathway in the document runs through a type 2 diabetes diagnosis.
We searched the preferred drug list effective July 27, 2026 for each product by name — 5,804 drug rows. Wegovy, Zepbound, Saxenda, Contrave, Qsymia, Xenical, orlistat and phentermine all return no matches, and no anti-obesity class heading appears anywhere in it. Ozempic and Trulicity do return matches, which is our check that the search was working rather than quietly failing. What a list omits is not by itself a coverage decision; the rule and the handbook above are the documents that decide, and they agree.
Two things we could not settle, said plainly. We did not find any Illinois document setting a general requirement that HealthChoice plans use the state's drug list — the closest current language is a May 2026 provider notice saying that one particular change applied to both fee-for-service and the plans, which is a statement about that change and not a standing rule. And the appeal deadlines below come from an HFS explainer that carries no date on its face and still lists a plan that has left the market, so we are giving you its numbers without an effective date and are not counting to a date from them.
The Illinois rule excludes these drugs from the pharmacy benefit. Under "Pharmacy Services Not Covered" it says "Items excluded from coverage include the following:" and the second entry is "Anorectic drugs or combinations including such drugs."
89 Ill. Adm. Code 140.441, Illinois General Assembly Joint Committee on Administrative Rules, effective May 2014 · source · read August 2026
The state's pharmacy handbook says it without the terminology. Under the heading "Prescription pharmacy items that are not covered under the Medical Assistance Program are:" one of the bullets reads "Weight loss drugs."
Illinois Department of Healthcare and Family Services, Handbook for Providers of Pharmacy Services, Chapter P-200, effective March 2016 · source · read August 2026
The state's criteria for this drug class name the products. They sort these medicines into groups, and the last group is headed "Not covered agents:" — under it sit Saxenda, Wegovy injection, Wegovy tablets and Zepbound. The same document lists, among the reasons a request is refused, that the "Medication requested is used either for obesity alone or in combination with another condition secondary to obesity (IL Medicaid policy)," and every approval pathway in it requires a type 2 diabetes diagnosis. ⚠ Two notes on this document: it is published on the prior-authorization site the state links from its own criteria page rather than on a state domain, and it prints an effective date of April 2025 while citing prescribing information dated 2026, so it has been revised since the date it shows.
Illinois Department of Healthcare and Family Services, Formal Criteria for the Illinois Medicaid Fee-For-Service Program, effective April 2025 · source · read August 2026
We searched the Illinois preferred drug list effective July 27, 2026 — 5,804 drug rows — for each product by name. Wegovy, Zepbound, Saxenda, Contrave, Qsymia, Xenical, orlistat and phentermine return no matches, and the list carries no anti-obesity or anorectic class heading at all. Ozempic and Trulicity do return matches, under "ANTIDIABETICS : INCRETIN MIMETIC AGENTS (GLP-1 RECEPTOR AGONISTS)," which is our control that the search worked. In that class Trulicity, Victoza and liraglutide are preferred, Ozempic tablets and Rybelsus preferred with prior authorization, and Ozempic injection, Mounjaro, Byetta and exenatide non-preferred.
Illinois Department of Healthcare and Family Services, Illinois Medicaid Preferred Drug List, effective July 2026 · source · read August 2026
If a HealthChoice Illinois plan denies you, the plan's own appeal comes first: "You may appeal within sixty (60) calendar days of the date on the Notice of Adverse Benefit Determination letter that you receive from your health plan." Then the state hearing, with a second date buried in the same sentence that decides whether your medicine continues: "you may ask for a State Fair Hearing within one hundred and twenty (120) calendar days of the date on the Notice of Appeal Resolution from your health plan, but you must ask for a State Fair Hearing within ten (10) calendar days of the date on the Notice of Appeal Resolution if you want to continue your services." ⚠ This document carries no date on its face and still lists a plan that no longer operates here, so treat the numbers as what Illinois publishes and confirm them against your own notice.
Illinois Department of Healthcare and Family Services, Bureau of Administrative Hearings · source · read August 2026
On whether the plans must follow the state list, here is the strongest current sentence we found, and it is narrower than a general rule. A May 2026 provider notice about GLP-1 drugs says "This change will apply to both the fee-for-service (FFS) program and Managed Care Organizations (MCOs) plans." That is a statement about that change. We looked for a standing requirement in the pharmacy rule, the state statute and the program's own pages and did not find one, so check your own plan's drug list rather than assuming.
Illinois Department of Healthcare and Family Services, Provider Notice, effective May 2026 · source · read August 2026
Medicaid is only one of the routes. If you have a commercial or employer plan, the rules are different and are on the employer plans page; Medicare has a federal rule of its own, on the Part D page.
If the appeal fails, or you cannot wait
Cash-pay telehealth is the fallback, not the bargain: you pay the whole cost yourself, and a covered prescription is almost always cheaper than any of these. Use this route when coverage has actually been exhausted, or when you need to start while an appeal runs.
These companies pay us a commission if you start care through the links below. That is how this site is funded, and it does not change what is written above. How we pay for this.
Prices in those notes were read from each company's own site in August 2026 and change often. Check the current number before you buy.
Every state we have verified is in the coverage matrix. Appeal routes and deadlines are on the procedures page.